Author:
Sanders Charles V.,Aldridge Kenneth E.
Abstract
Most anaerobic infections are polymicrobial and must be treated with agents active against a variety of both aerobic and anaerobic bacteria. Antimicrobial therapy is used both to contain infections and to treat those that have not been contained (bacteremia). Bacterial resistance, especially to penicillins and tetracyclines, but also to newer agents of other classes, continues to increase and often requires treatment with more than one drug. Combination therapy is also frequently necessary in serious infections, and is indicated for empiric management before receiving results of in vitro microbiology laboratory tests. However, recent results suggest that monotherapy for anaerobic infections may dominate in the future, although combination therapy has been the mainstay of antimicrobial therapy. Selection of an agent must take into account the site of infection and thus the bacteria most likely to be found. It should be kept in mind that in vitro susceptibility is not the only determinant of antimicrobial effectiveness. The pharmacology of the drug—absorption, distribution, concentration in body fluids and tissues, and metabolism—also plays an important role. Finally, the nature and severity of the underlying illness, the toxicity of the agent, and costs must be considered.
Reference57 articles.
1. Increasing resistance in anaerobes;Finegold SM.;Infect Surg,1984
2. Mechanisms of β-Lactam Resistance in Anaerobic Bacteria
3. Isolation of β-lactamase-producing Bacteroides strains associated with clinical failures with penicillin treatment of human orofacial infections
4. Clindamycin Compared with Penicillin for the Treatment of Anaerobic Lung Abscess
5. LodeH SamraH BaqueroFet al.Clindamycin versus penicillin in the treatment of lung abscess and necrotizing pneumonia: a multicenter study. Presented at the 27th interscience conference on antimicrobial agents and chemotherapy October 47 1987.